Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data

doi:10.19803/j.1672-8629.20230505

Abstract

Abstract: Objective To design and implement a database management platform for polypharmacy risk in common geriatric diseases based on real-world data, and to provide systematic support and reference for the risk monitoring and control of multiple drug use for common elderly diseases in China. Methods Based on the monitoring data standard of polypharmacy risk for common elderly diseases for medical institutions, a distributed data management platform was developed and established with the idea of building retrospective database and prospective database management platform. Results and Conclusion It is deployed in relevant medical institutions or regional medical information platforms to achieve data collection, data extraction and transformation, data query, analysis, statistics and other functions of data providing partners as a basic analysis environment. And it receives the analysis program of polypharmacy use for common diseases of the elderly, completes the polypharmacy analysis task of common diseases of the elderly in a single center in the local, and provides the query and submission function of the analysis structure. Through the construction of the data management platform, it could provide a basic data analysis environment for polypharmacy tasks for common geriatric diseases

Key words: elderly, common diseases, polypharmacy, data management, platform

CLC Number:

R954

LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098.

References

[1] NMPA. Circular on the Publication of the Guiding Principles on Real World Evidence to Support Drug Development and Review (Trial)[EB/OL].(2020-01-07)[2023-06-18]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200107151901190.html.
[2] JIANG X, LIU LR, ZHU H, et al.Enlightenment of foreign drug management systems on the drug management of the elderly in China[J].Herald of Medicine(医药导报), 2020, 39(8): 1166-1169.
[3] SHU T, CHEN WG, HOU YF, et al.Research and application of the sentinel hospital pharmacovigilance system based on HIS[J].China Pharmacy(中国药房), 2017, 28(25): 3468-3471.
[4] HOU YF, SONG HB, LIU HL, et al.Practice and discussion on active surveillance by China hospital pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 212-214.
[5] WANG LL, YANG Y, WANG SL.Application of the US FDA sentinel system and enlightenmen[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 81-87.
[6] LIU HL, ZHENG MJ, LI XL, et al.Overview of implementation of E2B (R3) guidelines by ICH founding regulatory members[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 594-596.
[7] NMPA. Regional Implementation Guide for Individual Case Safety Reporting E2B(R3).[EB/OL].(2019-11-22)[2023-06-18]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjzh/20191122091301498.html.
[8] HOU YF, DONG D, XIONG WY, et al.Developement of ICSR E2B Guideline[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 144-146.
[9] ZHANG RX, LIU QY, WANG HL, et al.Practice of a pharmacist-delivered service model and situation of drug-related problems among chronic elderly patients with polypharmacy in our hospital[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2022, 25(7): 630-634.
[10] National Key Research and Development Program (2018YFC2002400) Subject Groups. Expert consensus on safety management of multi-drug administration in elderly patients with co-morbidities in the elderly[J]. Chinese Journal of Health Care and Medicine(中华保健医学杂志), 2021, 23(5): 548-554.
[11] LI XY.Discussion on management mode of older adults with multimorbidity[J].Chinese Journal of Geriatric Heart Brain and Vessel Diseases(中华老年心脑血管病杂志), 2022, 24(5): 449-452.
[12] TANG YC, GU PY JIN S, et al. Clinical observation of polypharmacy in the elderly aged over 80 years[J]. Chinese Journal of Clinical Healthcare(中国临床保健杂志), 2018, 21(2): 156-159.
[13] National Health and Health Commission of the People's Republic of China. Health Industry Standard of the People's Republic of China(中华人民共和国卫生行业标准)[S/OL]. (2023-03-07)[2023-08-10]. http://www.nhc.gov.cn/cms-search/downFiles/864c23896af04e9fbaaa45a36751ab1c.pdf.

[1]	ZHU Yuanchao, ZHANG Yatong, HU Xin. Principles and measures of medication risk management in the elderly [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
[2]	ZHU Yuanchao, ZHAO Ming, HU Xin, SHI Hong. Pharmacist-led practice in the management of elderly patients with polypharmacy [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 817-821.
[3]	ZHANG Qingxia, ZHOU Liujun, LI Xiaoling, WANG Yuqin. Cefoperazone/sulbactam-related medication errors in the elderly and countermeasures [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 574-578.
[4]	ZHANG Yuan, HE Mei. Pharmaceutical care for a case of Parkinson's syndrome caused by trimetazidine hydrochloride tablets in an elderly patient with renal insufficiency [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 343-345.
[5]	SUN Jian, LIU Ziwei, LIU Ying, ZHANG Meiyu, LI Mengying, ZHANG Haiming, NIE Yinglan, QUAN Jianye, YAN Han, PENG Juan, LI Yucheng, YANG Shubin. Identification of chemical constituents in Jiawei Xiaoyao pills by UPLC-Q-TOF-MS^Ecombined with UNIFI informatics platform [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 181-190.
[6]	JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
[7]	CHU Yanqi, JIANG Yongxian, SHEN Jianghua, XING Xiaoxuan, ZHANG Qingxia, YAN Suying. Analgesia-related risks after thoracoscopic surgery in elderly patients [J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1023-1026.
[8]	DONG Hanshuo, SUN Li, ZHAO Xiaoxiao, WANG Lianxin, YU Xiaokang, XIE Yanming. Clinical characteristics and drug combination analysis of elemene injectable emulsion in the elderly in the real world [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 845-850.
[9]	MA Bingbing, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, LYU Jintao. Consideration of rational use of traditional Chinese medicine and pharmaceutical services for the elderly based on literature analysis [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 595-599.
[10]	ZHU Yuting, LI Maoxing. One case of agranulocytosis induced by methimazole tablets [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 345-348.
[11]	SUN Linxi, XIE Yanming, LI Yuanyuan, SUN Menghua, LI Xiangjie. Ways 2247 elderly patients use Lianhua Qingwen capsules in the real world [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 32-35.
[12]	SUN Chunquan, XIE Yanming, HOU Hengyue. Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 36-40.
[13]	ZHUANG Hongyan, LIU Shanshan, GUO Wei, XUE Chunmiao, HE Yue, ZHAO Yan. Chinese and western medicine pharmaceutical care for one diabetic foot patient with multiple complications [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 103-106.
[14]	CHANG Bingqing, GUO Yixian, ZHAO Hong, LAN Xiaoxi, SU Li, SUN Wanling. Adverse Reactions of Ultra-low Dose Decitabine in Elderly Patients with Intermediate- to high- risk Myelodysplastic Syndromes [J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 776-779.
[15]	ZHANG Dan, LYU Jintao, ZHANG Bing, LIN Zhijian, WU Huanzhang, ZHANG Xiaomeng. Construction and Application of Four-Dimensional and Chained Research Platform for Pharmacovigilance of Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 416-421.